8-K: AnaptysBio Reports Q1 FY27 Results, Jemperli Sales Surge

AnaptysBio announced fiscal first quarter 2027 financial results, highlighting robust global net sales for Jemperli and a new U.S. approval, while also providing updates on ongoing litigation and financial collaborations.

Summary

• AnaptysBio reported financial results for the fiscal first quarter ended September 30, 2026.
• Jemperli achieved global net sales of $1.0 billion for the nine months ended September 30, 2026, a 29% year-over-year increase.
• Jemperli received U.S. FDA approval for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer.
• The company's cash, cash equivalents, and investments totaled $153.0 million as of September 30, 2026.
• Collaboration revenue decreased to $30.3 million for the quarter, down from $76.3 million in the prior year, primarily due to a $50 million milestone in Q3 2025.
• General and administrative expenses increased significantly due to legal costs associated with the GSK and Tesaro lawsuit.
• Net income from continuing operations was $3.9 million ($0.13 per share) for the quarter, compared to $56.3 million ($2.02 per share) in the prior year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong commercial performance for Jemperli and a key regulatory approval, but tempered by ongoing litigation and a decrease in collaboration revenue.

Positives

• Jemperli's global net sales reached $1.0 billion for the nine months ended September 30, 2026, showing strong 29% year-over-year growth.
• Jemperli received U.S. FDA approval for a new indication in locally advanced rectal cancer (stage II and III MSI-H/dMMR).
• AnaptysBio continues to expect to achieve over $390 million in annualized Jemperli royalties by 2029, based on GSK's peak monotherapy sales guidance.
• The FDA target action date for Quimilza (imsidolimab) in generalized pustular psoriasis (GPP) is December 12, 2026.

Negatives

• Collaboration revenue decreased to $30.3 million for the three months ended September 30, 2026, from $76.3 million in the same period of 2025, largely due to the absence of a $50 million milestone recognized in Q3 2025.
• General and administrative expenses from continuing operations increased to $11.6 million from $1.1 million, significantly impacted by $4.8 million in legal costs for the GSK and Tesaro litigation.
• Net income from continuing operations decreased substantially to $3.9 million ($0.13 per share) from $56.3 million ($2.02 per share) year-over-year.
• Cash, cash equivalents, and investments decreased by $11.1 million during the quarter, primarily due to operating activities.

Risks

• The ongoing litigation with GSK and Tesaro, with a judgment anticipated in calendar Q4 2026 or Q1 2027, could impact the company's financial collaborations and Jemperli rights.
• The company's ability to protect its financial collaborations and return value to shareholders is subject to risks and uncertainties.
• Future clinical, commercial, and regulatory developments for Jemperli and Quimilza are subject to inherent risks and uncertainties.
• The company operates with a limited staff, which presents operational challenges.

Future Outlook

The company anticipates a judgment in its litigation with GSK and Tesaro in calendar Q4 2026 or Q1 2027. The FDA target action date for Quimilza is December 12, 2026. Regulatory submissions for Jemperli are expected in Japan in H1 2027 and in Europe and China in H2 2027, with a European decision expected in H2 2027. Data for AZUR-2 and JADE trials are expected in 2028. The company expects to achieve over $390 million in annualized Jemperli royalties by 2029 and anticipates paydown of remaining debt monetization in H2 2027.

Management Comments

• "Jemperlis continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer reinforce our confidence in its long-term potential in monotherapy indications," said Daniel Faga, president and chief executive officer.
• "We remain focused on protecting and returning the value of our financial collaborations to shareholders as we approach a judgment in our litigation with GSK and Tesaro in calendar Q4 2026 or Q1 2027 and the FDA target action date for Quimilza in December 2026."

Industry Context

StockSavvy.ai notes that AnaptysBio operates in the competitive biopharmaceutical sector, focusing on managing financial collaborations for key oncology and immunology drugs. The strong sales growth for Jemperli, a drug co-managed with GSK, reflects successful market penetration and expansion into new indications, a common strategy for biotechs seeking to maximize asset value. The ongoing litigation with GSK and Tesaro highlights the complex financial and legal landscape inherent in drug development and commercialization partnerships.

Comparison to Industry Standards

• Jemperli's global net sales of $1.0 billion for the nine months ended September 30, 2026, represent a 29% year-over-year growth, which is robust compared to many late-stage oncology drugs, though specific peer comparisons depend on the therapeutic area and stage of commercialization.
• The 12% royalty rate on net sales between $1.0 billion and $1.5 billion is a standard structure for collaboration agreements, aiming to incentivize further sales growth.
• The projected peak monotherapy sales guidance for Jemperli of over $2.7 billion by GSK suggests a belief in its significant market potential, aligning with blockbuster drug expectations in oncology.
• The decrease in collaboration revenue from $76.3 million to $30.3 million is primarily due to the absence of a large milestone payment in the prior year, a common fluctuation in biopharma revenue recognition which is not directly comparable to recurring revenue streams.

Legal Proceedings

• AnaptysBio is involved in litigation with GSK and Tesaro, with a post-trial hearing held on October 20, 2026. A judgment is anticipated in calendar Q4 2026 or Q1 2027. Anaptys is seeking reversion of Jemperli rights as a remedy.

Stakeholder Impact

• Shareholders: The decrease in net income and increase in legal costs may impact investor sentiment, while the strong Jemperli sales and potential litigation outcome could offer future upside.
• Creditors: The company's cash position of $153.0 million provides a buffer, but the ongoing litigation and debt monetization plans are factors to monitor.
• Partners (GSK, Vanda): Continued commercial success of Jemperli and progress on Quimilza are critical for collaboration revenue and future milestones.

Next Steps

• A judgment in the litigation with GSK and Tesaro is anticipated in calendar Q4 2026 or Q1 2027.
• The FDA is expected to make a decision on Quimilza by December 12, 2026.
• Regulatory submissions for Jemperli are planned for Japan in H1 2027 and Europe/China in H2 2027.
• The company anticipates paying down the remaining ~$270 million non-recourse debt monetization in calendar H2 2027.

Key Dates

Recommendation

The company shows strong commercial performance for Jemperli with significant sales growth and a new indication approval, which is positive. However, the substantial decrease in collaboration revenue year-over-year, increased legal expenses due to ongoing litigation, and a significant drop in net income warrant caution. The outcome of the GSK/Tesaro litigation and the FDA decision on Quimilza are key catalysts. Given the mixed signals, a 'hold' recommendation is appropriate pending further clarity on these critical events.

Keywords

Jemperli, AnaptysBio, financial results, collaboration revenue, litigation, GSK, Tesaro, Quimilza